Berlin Cures completes patient screening for Phase II Long COVID trial of BC 007 (Rovunaptabin).

Berlin Cures, a biotech company, has completed patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin) for Long COVID treatment. The trial has enrolled 114 patients across 14 trial centers in Europe, and first results are anticipated by autumn 2024. The trial progresses on schedule, marking a significant step forward in the company's pursuit to help millions of Long COVID patients.

April 23, 2024
3 Articles